SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-17-232046
Filing Date
2017-07-20
Accepted
2017-07-20 16:06:32
Documents
4
Period of Report
2017-07-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d427316d8k.htm 8-K 20250
2 EX-99.1 d427316dex991.htm EX-99.1 2517
3 EX-99.2 d427316dex992.htm EX-99.2 9081
4 GRAPHIC g427316g0720022933879.jpg GRAPHIC 4215
  Complete submission text file 0001193125-17-232046.txt   39105
Mailing Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746
Business Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Filer) CIK: 0001636282 (see all company filings)

IRS No.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37722 | Film No.: 17974422
SIC: 2834 Pharmaceutical Preparations